GREENFIELD, Ind. / Jun 05, 2023 / Business Wire / Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Goldman Sachs 44th Annual Global Healthcare Conference, June 12-13, 2023. Jeff Simmons, President and CEO, will participate in a fireside chat on Monday, June 12 at 5:40 p.m. ET (2:40 p.m. PT).
A live audio webcast will be available in the “Events and Presentations” section of Elanco’s investor website. A replay will be available for approximately 30 days.
ABOUT ELANCO
Elanco Animal Health (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ CSR framework – all to advance the health of animals, people and the planet. Learn more at www.elanco.com.
| Last Trade: | US$19.03 |
| Daily Change: | -0.17 -0.89 |
| Daily Volume: | 6,060,953 |
| Market Cap: | US$9.450B |
August 27, 2025 August 07, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
